MARKET

CPRX

CPRX

Catalyst Pharmaceuticals Inc
NASDAQ
16.63
-0.14
-0.83%
Closed 19:57 12/01 EST
OPEN
16.90
PREV CLOSE
16.77
HIGH
16.90
LOW
16.28
VOLUME
1.85M
TURNOVER
--
52 WEEK HIGH
18.39
52 WEEK LOW
5.24
MARKET CAP
1.73B
P/E (TTM)
27.35
1D
5D
1M
3M
1Y
5Y
Insider Sell: Catalyst Pharmaceuticals
Insider Sell: Catalyst Pharmaceuticals
MT Newswires · 11/23 17:09
Best Buy, Abercrombie & Fitch, Burlington Stores And Some Other Big Stocks Moving Higher On Tuesday
Benzinga · 11/22 16:19
Here is Why Growth Investors Should Buy Catalyst (CPRX) Now
Catalyst (CPRX) possesses solid growth attributes, which could help it handily outperform the market.
Zacks · 11/14 17:45
Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?
Here is how Catalyst Pharmaceutical (CPRX) and DICE Therapeutics, Inc. (DICE) have performed compared to their sector so far this year.
Zacks · 11/14 14:40
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Zacks · 11/14 13:30
Here's Why Catalyst Pharmaceuticals (NASDAQ:CPRX) Has Caught The Eye Of Investors
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Simply Wall St. · 11/11 14:49
UPDATE: Catalyst Pharmaceuticals Q3 Adj. EPS $0.26 Beats $0.19 Estimate
Benzinga · 11/09 21:47
BRIEF-Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results
Reuters · 11/09 21:40
More
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With the patient focus, the Company is engaged in developing a robust pipeline of cutting-edge, medicines for rare diseases. The Company's New Drug Application for FIRDAPSE (amifampridine) tablets 10 milligrams (mg) for the treatment of adults with Lambert-Eaton myasthenic syndrome (LEMS). The Company's FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. The FIRDAPSE is also used for the treatment of adult patients in Canada with LEMS. The Company is also focused on initiating clinical trials of amifampridine in other ultra-rare neuromuscular conditions.

Webull offers kinds of Catalyst Pharmaceuticals Inc stock information, including NASDAQ:CPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CPRX stock methods without spending real money on the virtual paper trading platform.